Dosing Every 12 Weeks After 2 Starter Doses at Weeks 0 and 41

STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who wiII be closely monitored and have regular follow-up. Patients may self-inject with STELARA® after physician approval and proper training. Patients should be instructed to follow the directions provided in the Medication Guide.

FOR PATIENTS WEIGHING

The recommended dose is…

45 mg dosed subcutaneously initially and 4 weeks later, followed by 45 mg every 12 weeks

FOR PATIENTS WEIGHING

The recommended dose is…

90 mg dosed subcutaneously initially and 4 weeks later, followed by 90 mg every 12 weeks*

*In patients weighing >220 lb. 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these patients.1

Reference: 1. STELARA® (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech, Inc.